Wednesday, July 8, 2026

Patent intelligence · US

US 6576786

Process for preparing substituted cyclopentane derivatives and novel crystalline structures thereof

expired A61PA61P31/12A61P31/16
Status expired
Linked drugs 1
Pipeline programs 6
Years to expiry 0
Applicant portfolio 72
Patent details — US 6576786

Quick answer

US 6576786 (Process for preparing substituted cyclopentane derivatives and novel crystalline structures thereof) is held by BioCryst Pharmaceuticals, Inc.. Status: expired. Granted Jun 10, 2003. Expires Jun 5, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
19
CPC classes
A61P, A61P31/12, A61P31/16

More from BioCryst Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12344585

    Crystalline salts of a plasma kallikrein inhibitor

    BioCryst Pharmaceuticals, Inc. · Expires Jun 26, 2045

    granted
  2. US 12162838

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Expires Dec 5, 2044

    granted
  3. US 12121503

    Antiviral treatments

    BioCryst Pharmaceuticals, Inc. · Expires Oct 17, 2044

    granted
  4. US 12116346

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Expires Oct 10, 2044

    granted
  5. US 12054492

    Imidazole-containing inhibitors of ALK2 kinase

    BioCryst Pharmaceuticals, Inc. · Expires Aug 1, 2044

    granted
  6. US 12043610

    Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

    BioCryst Pharmaceuticals, Inc. · Expires Jul 18, 2044

    granted
  7. US 11975003

    Methods and compositions for treatment of Zika virus infection

    BioCryst Pharmaceuticals, Inc. · Expires May 2, 2044

    granted
  8. US 11866418

    Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

    BioCryst Pharmaceuticals, Inc. · Expires Jan 4, 2044

    granted

Frequently asked questions

What is US patent 6576786?

US 6576786 (Process for preparing substituted cyclopentane derivatives and novel crystalline structures thereof) is held by BioCryst Pharmaceuticals, Inc.. Status: expired. Granted Jun 10, 2003. Expires Jun 5, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6576786?

BioCryst Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.

When does US 6576786 expire?

Our index shows an expiration date of Jun 5, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.